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OL-055 A Multiplex PCR-Based Reverse Line Blot
Hybridization (mPCR/RLB) strategy for subtyping
the staphylococcal cassette chromosome mec
(SCCmec) type IV in methicillin-resistant
Staphylococcus aureus
Ying Liu*,1, Fanrong Kong2, Meng Xiao3, Qinning Wang2,
Matthew O’Sullivan4, Gwendolyn L. Gilbert2. 1Department of
Dermatology, Beijing Children’s Hospital, Beijing, PR China;
2Centre for Infectious Diseases and Microbiology, Institute of
Clinical Pathology and Medical Research (ICPMR), Westmead,
New South Wales, Australia; 3Life Science College, Peking
University, Beijing, PR China; 4Western Clinical School,
University of Sydney, Sydney, Australia
Objectives: To develop and validate a multiplex PCR-based
reverse line blot hybridization (mPCR/RLB) strategy for subtyp-
ing staphylococcal cassette chromosome mec (SCCmec) type IV
methicillin-resistant Staphylococcus aureus (MRSA) strains.
Methods: Sixty primer pairs and 63 probes were designed on
the basis of the available sequences of each open-reading frame
(ORF) at GenBank, for the previously described SCCmec IV sub-
types. Probes were compared in silico to 18 whole genome
sequences complete genome and partial SCCmec gene of 6 non-
MRSA strains, including methicillin susceptible S. aureus and
methicillin resistant coagulase negative staphylococci.
Results: The mPCR/RLB assay classiﬁed a set of 93 MRSA strains
which possessed SCCmec type IV into 68 subtypes, including 46
subtypes for 52 well-characterized reference strains and 22 sub-
types for 41 clinical strains. The discriminatory power (Simpson
indices of diversity of 0. 987) is higher than other genotyping
methods to date. It can rapidly and simultaneously detect 43
samples with a turn-around time (including culturing of isolates,
DNA extraction, mPCR setup and running, and RLB hybridization)
of about two working days. This comparative analysis the po-
tential sensitivity of probes demonstrated that each of the 63
probes found homologous match with at least one GenBank MRSA
SCCmec type IV sequence.
Conclusion: The application of mPCR/RLB hybridization assay to
MRSA SCCmec IV subtyping can improve the speciﬁcity, discrimi-
natory power and throughput of the typing procedure. Moreover
it is also a good tool for near-real time infection control surveil-
lance and MRSA transmission tracking.
OL-056 Biochemical and immunological parameters
of amniotic ﬂuid from pregnant women with
herpes virus infection and congenital defects of
fetuses
Galyna Gaidai *,1, Larysa Bondarenko2. 1O.O. Bogomoletz
National Medical University, Kiev, Ukraine; 2SI Institute of
Pharmacology and Toxicology Academy of Medical Science of
Ukraine, Kiev, Ukraine
Early diagnosis and appropriate treatment of herpes virus in-
fections of pregnant women allows to minimize levels of inborn
herpes virus infections and fetal congenital defects.
Results of this pathology prenatal diagnostics often have am-
biguous and contradictory character. High levels of lethality and
fetal congenital defects incidence demand creation a complex of
diagnostic parameters for early stages of herpes virus infection
determination and fetal health status monitoring. Our aim was
to create complex of biochemical and immunological parameters
for amniotic ﬂuid investigation with the highest prognostic value
concerning inborn herpes virus infection and fetal congenital
defects incidence.
Materials and methods: Amniotic ﬂuid was obtained via trans-
abdominal amniocentesis from 24 pregnant women (18-35 years
old) with herpes virus infection (according virological analysis)
and fetal congenital defects (according to ultrasonic markers).
Antibidies IgM and IgG were determined by immunoenzymatic
analysis. Biochemical parameters were investigated on biochem-
ical analyzer “Cobas-Mira” (Austria).
Result: In ﬁrst group (10 women, 16-20 weeks gestation) there
were 1 positive result as to herpes virus IgG-antibidies, while in
second group (14 women, 21-24 weeks gestation) - 8. Changes in
biochemical parameters were statistically signiﬁcant even at 16
weeks of gestation. The highest changes were demonstrated for
levels of bilirubin, total protein, AST (increasing), glucose and
ALT (decreasing in comparison with norm).
Conclusions: Statistical analysis demonstrated that only complex
of biochemical, immunological, virological and ultrasonic inves-
tigations could have the highest prognostic value as to inborn
herpes virus infection and fetal congenital defects.
OL-057 The distribution and quantiﬁcation of
cytomegalovirus glycoprotein gB genotypes in
serum
Xuan Zhang*, Jun Fan, Meifang Yang, Hainv Gao, Xiaoming Chen,
Hong Zhao, Jianhua Hu, Weihang Ma. State Key Laboratory for
Diagnosis and Treatment of Infectious Diseases, First Afﬁliated
Hospital, Zhejiang University School of Medicine, Hangzhou,
China
Background: Based on the sequence variation in the N-terminus
of the UL55 gene, which encodes glycoprotein B (gB), human
cytomegalovirus (CMV) can be classiﬁed into four gBn genotypes.
This study determined the distribution and quantiﬁcation of CMV
gBn genotypes in a Chinese population of HSCT recipients and ex-
amined the correlations among the gBn genotype, pp65 antigen,
CMV gBn DNA, and clinical outcome.
Methods: The distribution of CMV gBn genotypes and the level of
gBn DNA were detected by real-time PCR.CMV-positive pp65 cells
were identiﬁed by immunohistochemical staining.
Result: The distribution of gB genotypes was as follows: gBn1,
60% of patients; gBn2, 13.3%; mixed gBn1 and gBn3 infection,
26.7%; and gBn4 and other mixed infections, 0%. The detected
level of CMV gB DNA correlated well with the number of CMV-
positive pp65 cells (r=0.514).
Conclusion: The distribution of CMV gBn genotypes in a Chinese
HSCT recipients were determined. And gBn1 genotype is predom-
inant. A statistical relationship between the different gB types
and the clinical outcome could be not determined, owing to the
small sample size in this study.
OL-058 Methylation status of hepatic IGF-II promoter 3 in
HBV-related chronic liver diseases
Jing Qian*, Dengfu Yao, Yucheng Shen, Shanshan Li, Yinzhu Bian.
Research Center of Clinical Medicine, Afﬁliated Hospital of
Nantong University, Nantong, China
Objective: To investigated the promoter methylation status of
IGF-II in hepatoma model and human HCC tissues for exploring its
mechanism at the occurrence of HCC.
Methods: Hepatoma models were induced with 2-FAA on male
SD rats. Morphological changes of livers were observed by H&E
staining. The CpG island methylation status of rat and human
IGF-II gene P was observed by MSP.
Results: IGF-II was overexpressed in hepatocytes from granule-
like degeneration to atypical hyperplasia and HCC development.
The levels of serum IGF-II expressions in HCC were signiﬁcantly
higher than any of other groups (P<0.01). The incidence of
P2 methylation was 100% in normal, 83.3% in degeneration,
11.1% in precancerous, and 0% in HCC group, respectively. The
rates of IGF-II P3 methylation in was 0% in human HCC, 47.5%
in their surrounding, and 100% in normal tissues, respectively,
with signiﬁcant differences among them (P=0.000). No signiﬁ-
cant signiﬁcance was found between the methylation rates of
IGF-II P3 and clinical parameters. However, the methylation
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rates of IGF-II P3 in the adjacent tissues in poorly differentiated
HCC were lower than well-differentiated ones (P=0.000); At the
same time, the methylation rates of IGF-II P3 in HBsAg-positive
HCC was signiﬁcantly lower than those with HBsAg-negative
(P=0.026).
Conclusions: The methylation status of IGF-II promoter is closely
related to the malignant transformation of hepatocytes at the
early stage of HCC, and helpful to explore the pathogenesis of
HCC.
OL-059 Effect of blocking expression of human
augmenter of liver regeneration (hALR) on the
expression of transforming growth factor-α
(TGF-α) and epidermal growth factor receptor in
HepG2
Shan Liang*, Hang Sun, Xinguo Wang, Songli Xie, Qi Liu. Institute
for Viral Hepatitis, Chongqing University of Medical Sciences;
Ministry of Education Key Laboratory of Molecular Biology for
Infectious Disease, Chongqing, China
Objective: To investigate the effect of blocking the expression
of hALR with small interfering RNA (siRNA) targeting ALR on the
expression of TGF-α and EGFR of HCC cell line HepG2.
Methods: The expressing siRNA plasmid pSIALR-A targeting hALR
and the unrelated control plasmid pSIALR-B were transfected
into HepG2 cells with lipofectamine 2000 methods, respec-
tively. The expression of green ﬂuorescent protein was observed
under a ﬂuorescent microscope to calculate transfection efﬁ-
ciency. The protein level of hALR in the transfected cells was
measured by immunocytochemistry to determine the inhibitory
effect. According to different plasmid transfection, HepG2 cells
were divided into three groups: transfection group (transfected
pSIALR-A), the control group (transfected pSIALR-B), blank con-
trol group (non-transfected with the recombinant plasmid). The
expression of TGF-α in the cell culture supernatant was detected
by radioimmunoassay, the expression of EGFR was detected by
Western blot.
Results: In transfection group, blank group and the unre-
lated control group, expression of TGF-α is (5.27±0.86) pg/ml,
(7.92±2.65) pg/ml and (6.50±1.28) pg/ml, respectively,the dif-
ference of transfection group and blank group, transfection
group and the unrelated control group was statistically signiﬁ-
cant (P<0.05); the relative expression of EGFR is 0.946±0.136,
1.115±0.606 and 1.131±0.509, respectively,the difference of
transfection group and blank group, transfection group and the
unrelated control group was statistically signiﬁcant (P<0.05).
Conclusion: In the complex cytokine network which promotes
the growth of hepatomas, augmenter of liver regeneration played
an important role in the occurrence and development of hep-
atic carcinoma not only by stimulating hepatomas proliferation
directely but also by up-regulating the expression level of TGF-α
and EGFR.
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OL-060 Dose-dependent effects of antitubercular drug on
liver, lung and spleen contents of free amino
acids
Larysa Bondarenko*, Natalia Saprykina, Ganna Shayakhmetova,
Valentina Kovalenko. SI Institute of Pharmacology and
Toxicology Academy of Medical Sciences of Ukraine
Introduction: Further optimization of tuberculosis chemotherapy
requires a comprehensive evaluation of the effects of antituber-
cular drugs on metabolic processes in liver and Mycobacterium
tuberculosis-targeted organs.
Materials and Methods: Wistar albino male rats (body weight
(bw), 160–200 g) were divided into three groups: group I re-
ceived pyrazinamide per os at a dose of 1000 mg/kg bw/day,
group II - a dose of 2000 mg/kg bw/day, in both group it was given
for 60 days; the control group was composed of intact animals.
The contents of free amino acids in the liver, lung and spleen
were determined using an amino acid analyzer ÀÀÀ-881 (Czech
Republic).
Results and Discussion: The study of the effects of pyrazinamide
on the liver, lung and spleen contents of free amino acids in
the rats showed the largest number of changes in the liver at
a dose 1000 mg/kg bw/day and in the lung and spleen - at a
dose 2000mg/kg bw/day. At a dose 2000mg/kg in the lung, the
content of free amino acids at the level of 18 amino acids and
total sum of amino acids signiﬁcantly differed from controls. In
the spleen, this difference was observed at the level of 14 amino
acids and total sum of amino acids.
Conclusions: The study of the inﬂuence of pyrazinamide on liver,
lung and spleen contents of free amino acids allows to fully esti-
mate the dose-dependent effects of this substance on metabolic
processes in these organs.
OL-061 A subunit vaccine consisting of fusion protein
Ag85B-MPT64190-198-Mtb8.4 and adjuvant of
dimethyl-dioctyldecyl ammonium and BCG
polysaccharide nucleic acid enhances
BCG-primed protection against Mycobacterium
tuberculosis infection in mice
Bingdong Zhu*,1, Bingxiang Wang2, Yu Luo1, Wenwen Jiang1,
Zejiao Da1, Hongjuan Yu1, Zhijiao Tang3, Honghai Wang4,
Ying Zhang1,5. 1Lanzhou Center for Tuberculosis Research &
Institute of Pathogenic Biology, Lanzhou University, China;
2Lanzhou Institute of Biology Product, China; 3ABSL-3 Lab,
Wuhan University, China; 4Institute of Genetics, Fudan
University, China; 5Department of Molecular Microbiology and
Immunology, Bloomberg School of Public Health, John Hopkins
University, USA
Background: We constructed one candidate subunit vaccine
AMDB made up of a fusion protein Ag85B-Mpt64190-198-Mtb8.4
(AMM), and a compound adjuvant consisting of dimethyl-
dioctyldecyl ammonium bromide (DDA) and BCG polysaccharide
nucleic acid (BCG-PSN). The immunogenicity of this vaccine and
its capability to boost BCG primed immunity were investigated.
Method: To investigate the immunogenicity of the vaccine, mice
were immunized subcutaneously with the vaccine with a 2-week
interval between the immunizations. Furthermore, AMM in DDA
with or without BCG-PSN was used to boost BCG-primed immunity
once, twice and thrice 6-10 weeks after BCG injection with 2
weeks interval respectively in C57BL/6 mice. The immune reac-
tion, protective efﬁcacy and pathology were determined after
vaccine immunization.
Results: The subunit vaccine based on the fusion protein AMM
induced more effective humoral and cell-mediated immune re-
sponses than the one based on the single antigen Ag85B. Mice
immunized with BCG primed and boosted by AMM twice produced
a stronger immune response than the one immunized with BCG
alone or the one boosted by Ag85B and afforded signiﬁcant
protection against M. tuberculosis infection. Lung histopathol-
ogy examination indicated that the AMM vaccine containing DDA
and BCG-PSN as adjuvant could reduce the pathological lesion
compared with the AMM vaccine containing DDA alone.
Conclusion: Subunit vaccine AMDB induced a strong Th1-type
immune response. Based on BCG priming, AMDB vaccine boosting
twice could enhance the immunogenicity and protection against
M. tuberculosis in mice.
